Expression of lymphatic markers in angiokeratomas

Journal of Cutaneous Pathology

Volumn 41, Issue 7, 2014, Pages 576-581

  Wang, Lei ^a   Yuan, Wei ^b   Geng, Songmei ^c   Xiong, Ya ^d   Zhang, Dezhi ^e   Zhao, Xiaoqing ^f   Li, Shenqiu ^g   Bi, Xinling ^h   Gao, Tianwen ^a   Wang, Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b ZUNYI MEDICAL UNIVERSITY   (China)

^c MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^d THIRD MILITARY MEDICAL UNIVERSITY   (China)

^e Xinjiang Uygur Autonomous Region Hospital   (China)

^f SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^g HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^h SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

angiokeratoma; D2 40; lymphatic; Prox1; vascular

Indexed keywords

TUMOR MARKER;

BIOSYNTHESIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION REGULATION; HEMANGIOKERATOMA; HUMAN; MALE; METABOLISM; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; SKIN TUMOR;

ANGIOKERATOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84903458696     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12349     Document Type: Article

References (28)

1. Sangüeza OP, Requena L,. Pathology of vascular skin lesions: clinicopathologic correlations. Totowa, New Jersey: Humana Press, 2003; 86.
2. Imperial R, Helwig EB,. Angiokeratoma: a clinicopathologic study. Arch Dermatol 1967; 95: 166.
3. Epinette WW, Norins AL, Drew AL, Zeman W, Patel V,. Angiokeratoma corporis diffusum with alpha-l-fucosidase deficiency. Arch Dermatol 1973; 107: 754.
4. Kanitakis J, Allombert C, Doebelin B, et al. Fucosidosis with angiokeratoma. Immunohistochemical & electronmicroscopic study of a new case and literature review. J Cutan Pathol 2005; 32: 506.
5. Molho-Pessach V, Bargal R, Abramowitz Y, et al. Angiokeratoma corporis diffusum in human beta-mannosidosis: report of a new case and a novel mutation. J Am Acad Dermatol 2007; 57: 407.
6. Kelly B, Kelly E,. Angiokeratoma corporis diffusum in a patient with no recognizable enzyme abnormalities. Arch Dermatol 2006; 142: 615.
7. Yokota M, Koji M, Yotsumoto S,. Histopathologic and ultrastructural studies of angiokeratoma corporis diffusum in Kanzaki disease. J Dermatol 1995; 22: 10.
8. Patrizi A, Neri I, Trevisi P, Landi C, Bardazzi F,. Congenital angiokeratoma of Fordyce. J Eur Acad Dermatol Venereol 1998; 10: 195.
9. Haidopoulos DA, Rodolakis AJ, Elsheikh AH, Papaspirou I, Diakomanolis E,. Vulvar angiokeratoma following radical hysterectomy and radiotherapy. Acta Obstet Gynecol Scand 2002; 81: 466.
10. Stewart CJ, Chan T, Platten M,. Acquired lymphangiectasia ('lymphangioma circumscriptum') of the vulva: a report of eight cases. Pathology 2009; 41: 448.
11. Haye KR, Rebello DJ,. Angiokeratoma of Mibelli. Acta Derm Venereol 1961; 41: 56.
12. Dave VK, Main RA,. Angiokeratoma of Mibelli with necrosis of the fingertips. Arch Dermatol 1972; 106: 726.
13. Franke FE, Steger K, Marks A, Kutzner H, Mentzel T,. Hobnail hemangiomas (targetoid hemosiderotic hemangiomas) are true lymphangiomas. J Cutan Pathol 2004; 31: 362.
14. Carlson JA, Daulat S, Goodheart HP,. Targetoid hemosiderotic hemangioma-a dynamic vascular tumor: report of 3 cases with episodic and cyclic changes and comparison with solitary angiokeratomas. J Am Acad Dermatol 1999; 41: 215.
15. Flanagan BP, Helwig EB,. Cutaneous lymphangioma. Arch Dermatol 1977; 113: 24.
16. Wigle JT, Oliver G,. Prox1 function is required for the development of the murine lymphatic system. Cell 1999; 98: 769.
17. Wigle JT, Harvey N, Detmar M, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002; 7: 1505.
18. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003; 162: 575.
19. Hong YK, Harvey N, Noh YH, et al. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn 2002; 225: 351.
20. Schacht V, Ramirez MI, Hong YK, et al. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003; 22: 3546.
21. Castro EC, Galambos C,. Prox-1 and VEGFR3 antibodies are superior to D2-40 in identifying endothelial cells of lymphatic malformations-a proposal of a new immunohistochemical panel to differentiate lymphatic from other vascular malformations. Pediatr Dev Pathol 2009; 12: 187.
22. Wilting J, Papoutsi M, Christ B, et al. The transcription factor Prox1 is a marker for lymphatic endothelial cells in normal and diseased human tissues. FASEB J 2002; 16: 1271.
23. Miettinen M, Wang ZF,. Prox1 transcription factor as a marker for vascular tumors-evaluation of 314 vascular endothelial and 1086 nonvascular tumors. Am J Surg Pathol 2012; 36: 351.
24. Ordõñez NG,. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005; 36: 372.
25. Bhawan J, Silva C, Taungjaruwinai WM,. Inconsistent immunohistochemical expression of lymphatic and blood endothelial cell markers in cutaneous lymphangiomas. J Cutan Pathol 2013; 40: 801.
26. Partanen TA, Alitalo K, Miettinen M,. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999; 86: 2406.
27. Lawley LP, Cerimele F, Weiss SW, et al. Expression of Wilms tumor 1 gene distinguishes vascular malformations from proliferative endothelial lesions. Arch Dermatol 2005; 141: 1297.
28. Trindade F, Tellechea O, Torrelo A, Requena L, Colmenero I,. Wilms tumor 1 expression in vascular neoplasms and vascular malformations. Am J Dermatopathol 2011; 33: 569.